Home  »  Business   »  Highlights from the Ratings and Financial Report f...

Highlights from the Ratings and Financial Report for Halozyme Therapeutics Inc. (HALO)

Halozyme Therapeutics Inc. (NASDAQ:HALO) went down by -4.40% from its latest closing price compared to the recent 1-year high of $52.98. The company’s stock price has collected -10.15% of loss in the last five trading sessions. Barron’s reported on 04/13/22 that Antares Pharma Stock Soars After $960 Million Halozyme Buyout

Is It Worth Investing in Halozyme Therapeutics Inc. (NASDAQ :HALO) Right Now?

Halozyme Therapeutics Inc. (NASDAQ:HALO) scored a price-to-earnings ratio above its average ratio, recording 15.21 x from its present earnings ratio. Plus, the 36-month beta value for HALO is at 1.22. Opinions of the stock are interesting as 5 analysts out of 6 who provided ratings for Halozyme Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


The average price from analysts is $53.50, which is $2.44 above the current price. HALO currently public float of 136.32M and currently shorts hold a 6.53% ratio of that float. Today, the average trading volume of HALO was 1.17M shares.

HALO’s Market Performance

HALO stocks went down by -10.15% for the week, with a monthly drop of -2.91% and a quarterly performance of 9.61%, while its annual performance rate touched 13.08%. The volatility ratio for the week stands at 4.34% while the volatility levels for the past 30 days are set at 4.06% for Halozyme Therapeutics Inc. The simple moving average for the period of the last 20 days is -8.40% for HALO stocks with a simple moving average of 13.68% for the last 200 days.

Analysts’ Opinion of HALO

Many brokerage firms have already submitted their reports for HALO stocks, with SVB Leerink repeating the rating for HALO by listing it as a “Outperform.” The predicted price for HALO in the upcoming period, according to SVB Leerink is $52 based on the research report published on May 23rd of the current year 2022.

SVB Leerink gave a rating of “Outperform” to HALO, setting the target price at $56 in the report published on May 17th of the previous year.

HALO Trading at -3.55% from the 50-Day Moving Average

After a stumble in the market that brought HALO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.33% of loss for the given period.

Volatility was left at 4.06%, however, over the last 30 days, the volatility rate increased by 4.34%, as shares sank -9.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.39% upper at present.

During the last 5 trading sessions, HALO fell by -10.15%, which changed the moving average for the period of 200-days by +22.31% in comparison to the 20-day moving average, which settled at $49.31. In addition, Halozyme Therapeutics Inc. saw 12.88% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at HALO starting from Torley Helen, who sale 50,000 shares at the price of $39.82 back on Nov 08. After this action, Torley Helen now owns 537,160 shares of Halozyme Therapeutics Inc., valued at $1,990,768 using the latest closing price.

MATSUI CONNIE, the Director of Halozyme Therapeutics Inc., sale 32,000 shares at $40.38 during a trade that took place back on Nov 05, which means that MATSUI CONNIE is holding 181,983 shares at $1,292,113 based on the most recent closing price.

Stock Fundamentals for HALO

Current profitability levels for the company are sitting at:

  • +62.24 for the present operating margin
  • +81.64 for the gross margin

The net margin for Halozyme Therapeutics Inc. stands at +90.84. Equity return is now at value 202.60, with 38.90 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 7.91.